Displaying 161 - 180 of 249 results

NIAMS Remembers Scientist Emeritus Paul Plotz, M.D.

https://www.niams.nih.gov/newsroom/announcements/niams-remembers-scientist-emeritus-paul-plotz-md

NIAMS is saddened to share the news that Paul Plotz, M.D., who dedicated nearly four decades of service to science at the NIH, passed away on January 13, 2024, at the age of 86 after a long illness. Dr. Plotz was a world-renowned rheumatologist, immunologist, and researcher known internationally as an expert in myositis, an inflammatory muscle disease and rare autoimmune condition. He retired from NIH in 2011 after serving in a variety of leadership roles, including as chief of the NIAMS Arthritis and Rheumatism Branch, as well as acting scientific director and acting deputy director. He also was senior

From the Deputy Director: Piecing Together the Autoimmune Disease Puzzle

https://www.niams.nih.gov/about/about-the-director/letter/piecing-together-autoimmune-disease-puzzle

In her December 2021 letter, NIAMS Director Dr. Lindsey Criswell discussed the launch of the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program. This new initiative builds upon the progress of the prior AMP RA/SLE project, which greatly advanced our understanding of the mechanisms that drive disease in rheumatoid arthritis (RA) and lupus.

Scientific Director

https://www.niams.nih.gov/about/niams-leadership/scientific-director-of-intramural-research

The Office of the Scientific Director (OSD) is responsible for oversight, review, and administration of the Intramural Research Program (IRP) at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The OSD has several key functions, including planning, coordinating, and directing the basic and clinical scientific research programs conducted within the IRP.

Community Collaboration Advances NIAMS Resource Development

https://www.niams.nih.gov/about/about-the-director/letter/community-collaboration-advances-niams-resource-development

When I joined NIAMS three and a half years ago, I talked about my commitment to collaboration and learning from the NIAMS community in my first director’s letter. Since then, we have done a lot of both collaborating and learning! I highly value the input from the NIAMS community on the development of our resources and in determining the direction of our research so that we are addressing the needs of the various audiences we serve, from researchers and medical providers to patients and caregivers. NIAMS regularly solicits feedback to understand audience needs. Over the past two years, the NIAMS

R03 Information for NIAMS K Award Recipients

https://www.niams.nih.gov/grants-funding/research-training-and-career-development-programs/r03-information-niams-k-award

NIAMS Small Grant Program for New Investigators (R03) Read the NOFO: Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed) Program Purpose: The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is seeking small grant (R03) applications to stimulate

NIAMS Aims to Broaden Support for Our Mission By Expanding Our Funding Approach

https://www.niams.nih.gov/about/about-the-director/letter/niams-aims-broaden-support-our-mission-expanding-our-funding

NIAMS strives to advance the best science on arthritis, musculoskeletal, and skin diseases, which have a profound effect on the quality of life for millions of Americans. To further the NIAMS mission—and importantly, to best steward the resources allocated to us by Congress—we are making some changes to our funding approach and strategy. These include reserving a larger portion of funding to support applications beyond the payline (which is the funding percentile up to which almost all grant applications will be funded). Historically, NIAMS has paid most of its applications according to a strict payline-driven approach, with limited funds available

Typically materials from NIAMS that are more than 5 years old will be archived.